

Table SI. Risk of adverse events in singleton pregnancies, psoriatic arthritis (PsA) (n=896). Pregnancies without psoriasis and PsA serves as reference. Excluding women who have a diagnosis of rheumatoid arthritis (RA) after their latest PsA-diagnosis

Adverse event	n (%)	OR (95% CI)	Model 1 ^a OR (95% CI)	Model 2 ^b OR (95% CI)
Gestational diabetes ^c	23 (2.6)	1.40 (0.91–2.16)	1.36 (0.89–2.1)	1.23 (0.79–1.91)
Gestational hypertension ^c	36 (4.0)	1.76 (1.24–2.49)	1.72 (1.21–2.45)	1.57 (1.08–2.27)
Antepartum haemorrhage	24 (2.7)	1.07 (0.71–1.6)	1.04 (0.70–1.57)	1.03 (0.67–1.57)
Venous thromboembolism	5 (0.6)	2.49 (1.03–5.99)	2.32 (0.96–5.61)	2.33 (0.97–5.62)
Pre-eclampsia	44 (4.9)	1.52 (1.12–2.07)	1.61 (1.18–2.19)	1.42 (1.01–1.99)
Elective caesarean	117 (13.1)	1.60 (1.30–1.98)	1.41 (1.14–1.74)	1.34 (1.07–1.68)
Emergency caesarean	95 (10.6)	1.15 (0.92–1.44)	1.21 (0.96–1.51)	1.09 (0.85–1.39)
Preterm birth (<37 weeks)	52 (5.8)	1.17 (0.88–1.55)	1.22 (0.92–1.62)	1.19 (0.89–1.59)
Very or extremely preterm birth (<32 gestational weeks)	6 (0.7)	0.80 (0.36–1.79)	0.84 (0.38–1.88)	0.78 (0.32–1.88)
Moderate preterm birth (32–36 weeks)	46 (5.1)	1.24 (0.92–1.68)	1.29 (0.96–1.75)	1.27 (0.93–1.72)
Apgar <7	17 (1.9)	0.92 (0.57–1.48)	0.99 (0.62–1.6)	0.97 (0.58–1.62)
Small for gestational age (SGA)	13 (1.5)	0.66 (0.38–1.13)	0.69 (0.40–1.2)	0.67 (0.38–1.18)
Low birth weight	29 (3.2)	0.93 (0.65–1.35)	0.99 (0.68–1.43)	0.97 (0.66–1.42)
Stillbirth	4 (0.4)	1.21 (0.45–3.25)	1.27 (0.47–3.38)	1.04 (0.33–3.22)
Congenital malformations	43 (4.8)	1.15 (0.85–1.55)	1.13 (0.83–1.53)	1.11 (0.81–1.53)

^aModel 1: adjusted for country, maternal age, parity. ^bModel 2: adjusted for country, maternal age, parity, body mass index, hypertension, diabetes, mellitus, depression, smoking. ^cOnly women without prescriptions of antidiabetic and antihypertensive medications up to 1 year prior to pregnancy were eligible to develop gestational diabetes or hypertension, respectively.
OR: odds ratio; CI: confidence interval.

Table SII. Risk of adverse events in singleton pregnancies, psoriatic arthritis (PsA) (n=882). Pregnancies without psoriasis and PsA serves as reference. Excluding women who have a diagnosis of rheumatoid arthritis (RA) after their latest PsA diagnosis, and more frequent RA diagnoses than PsA diagnoses

Adverse event	n (%)	OR (95% CI)	Model 1 ^a OR (95% CI)	Model 2 ^b OR (95% CI)
Gestational diabetes ^c	23 (2.6)	1.42 (0.92–2.19)	1.39 (0.90–2.14)	1.24 (0.80–1.94)
Gestational hypertension ^c	35 (4.0)	1.73 (1.21–2.48)	1.70 (1.19–2.43)	1.54 (1.06–2.25)
Antepartum haemorrhage	24 (2.7)	1.09 (0.72–1.63)	1.06 (0.71–1.59)	1.05 (0.69–1.6)
Venous thromboembolism	5 (0.6)	2.53 (1.05–6.08)	2.37 (0.98–5.71)	2.37 (0.98–5.72)
Pre-eclampsia	43 (4.9)	1.51 (1.11–2.07)	1.59 (1.16–2.18)	1.40 (0.99–1.97)
Elective caesarean	114 (12.9)	1.59 (1.28–1.96)	1.40 (1.13–1.73)	1.33 (1.06–1.66)
Emergency caesarean	95 (10.8)	1.17 (0.94–1.46)	1.23 (0.98–1.54)	1.10 (0.87–1.41)
Preterm birth (<37 weeks)	52 (5.9)	1.19 (0.90–1.58)	1.24 (0.93–1.65)	1.21 (0.90–1.62)
Very or extremely preterm birth (<32 gestational weeks)	6 (0.7)	0.82 (0.37–1.82)	0.86 (0.38–1.91)	0.79 (0.33–1.91)
Moderate preterm birth (32–36 weeks)	46 (5.2)	1.26 (0.94–1.71)	1.31 (0.97–1.78)	1.29 (0.95–1.75)
Apgar <7	17 (1.9)	0.93 (0.58–1.51)	1.01 (0.63–1.63)	0.99 (0.59–1.64)
Small for gestational age (SGA)	13 (1.5)	0.67 (0.39–1.15)	0.70 (0.41–1.22)	0.68 (0.38–1.2)
Low birth weight	29 (3.3)	0.95 (0.66–1.37)	1.00 (0.69–1.45)	0.98 (0.67–1.44)
Stillbirth	4 (0.5)	1.23 (0.46–3.3)	1.29 (0.48–3.44)	1.05 (0.34–3.26)
Congenital malformations	41 (4.6)	1.11 (0.81–1.51)	1.09 (0.80–1.49)	1.10 (0.80–1.52)

^aModel 1: adjusted for country, maternal age, parity. ^bModel 2: adjusted for country, maternal age, parity, body mass index, hypertension, diabetes, mellitus, depression, smoking. ^cOnly women without prescriptions of antidiabetic and antihypertensive medications up to 1 year prior to pregnancy were eligible to develop gestational diabetes or hypertension, respectively.
OR: odds ratio; CI: confidence interval.

Table SIII. Risk of adverse pregnancy and birth events in singleton pregnancies with and without psoriasis. Pregnancies without psoriasis serves as reference. Body mass index and maternal age are continuous variables

Adverse event	Psoriasis n=8,097 n (%)	Without psoriasis n=943,846 n (%)	Crude OR (95% CI)	Model 1 ^a OR (95% CI)	Model 2 ^b OR (95% CI)
Gestational diabetes ^c	215 (2.7)	17,418 (1.8)	1.45 (1.26–1.68)	1.36 (1.17–1.57)	1.21 (1.03–1.41)
Gestational hypertension ^c	231 (2.9)	21,988 (2.3)	1.23 (1.08–1.41)	1.25 (1.10–1.44)	1.16 (1.00–1.33)
Antepartum haemorrhage	211 (2.6)	23,712 (2.5)	1.04 (0.90–1.19)	1.06 (0.92–1.22)	0.98 (0.84–1.14)
Venous thromboembolism	19 (0.2)	2,126 (0.2)	1.04 (0.66–1.64)	0.97 (0.61–1.55)	0.87 (0.53–1.43)
Pre-eclampsia	323 (4.0)	30,954 (3.3)	1.23 (1.09–1.38)	1.28 (1.14–1.44)	1.15 (1.01–1.3)
Elective caesarean	835 (10.3)	80,817 (8.6)	1.23 (1.14–1.33)	1.17 (1.08–1.26)	1.10 (1.02–1.2)
Emergency caesarean	863 (10.7)	88,140 (9.3)	1.16 (1.08–1.25)	1.16 (1.08–1.25)	1.09 (1.00–1.18)
Preterm birth (<37 weeks)	436 (5.4)	47,207 (5.0)	1.08 (0.98–1.19)	1.10 (1.00–1.22)	0.98 (0.88–1.09)
Very or extremely preterm birth (<32 gestational weeks)	70 (0.9)	7,852 (0.8)	1.04 (0.81–1.33)	1.07 (0.84–1.37)	0.91 (0.68–1.23)
Moderate preterm birth (32–36 weeks)	366 (4.5)	39,355 (4.2)	1.09 (0.98–1.21)	1.11 (1.00–1.23)	0.99 (0.88–1.12)
Apgar <7	154 (1.9)	19,470 (2.1)	0.92 (0.78–1.08)	0.98 (0.83–1.15)	0.90 (0.75–1.09)
Small for gestational age (SGA)	175 (2.2)	20,693 (2.2)	0.99 (0.85–1.15)	1.02 (0.87–1.19)	0.95 (0.81–1.12)
Low birth weight	300 (3.7)	32,643 (3.5)	1.07 (0.95–1.21)	1.09 (0.97–1.23)	0.98 (0.86–1.12)
Stillbirth	23 (0.3)	3,471 (0.4)	0.77 (0.50–1.18)	0.82 (0.53–1.25)	–
Congenital malformations	346 (4.3)	39,739 (4.2)	1.02 (0.91–1.13)	1.03 (0.93–1.15)	1.01 (0.90–1.13)

Categories of body mass index (BMI) and maternal age were used, given that using a continuous variable would imply an assumption of a linear relationship between exposure and outcome, which may not be true for BMI and maternal age where both low and high values have been associated with adverse outcomes. We did, however, also conduct a sensitivity analysis to determine the effect of this choice of analysis strategy. With BMI and maternal age as continuous variables, the results of psoriasis vs. population remained practically unchanged.

^aModel 1: adjusted for country, maternal age, parity. ^bModel 2: adjusted for country, maternal age, parity, BMI, hypertension, diabetes, mellitus, depression, smoking. ^cOnly women without prescriptions of antidiabetic and antihypertensive medications up to 1 year prior to pregnancy were eligible to develop gestational diabetes or hypertension, respectively.